IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR?S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY
Author(s): ,
Marek Trn?ný
Affiliations:
Department of Hematology,Charles University Hospital,Prague,Czech Republic
,
Thierry Lamy
Affiliations:
Department of Hematology,Hôpital Pontchaillou,Rennes,France
,
Jan Walewski
Affiliations:
Department of Lymphoid Malignancies,Maria Sklodowska-Curie Memorial Institute and Oncology Centre,Warsaw,Poland
,
David Belada
Affiliations:
Fourth Department of Internal Medicine ? Haematology,Charles University Hospital and Faculty of Medicine,Hradec Králové,Czech Republic
,
Jiri Mayer
Affiliations:
Department of Internal Medicine, Hematology and Oncology,University Hospital Brno,Brno,Czech Republic
,
John Radford
Affiliations:
Department of Medical Oncology,The University of Manchester and The Christie NHS Foundation Trust,Manchester,United Kingdom
,
Wojciech Jurczak
Affiliations:
Department of Hematology,Jagiellonian University,Kraków,Poland
,
Franck Morschhauser
Affiliations:
Centre Hospitalier Universitaire Régional de Lille,Lille,France
,
Julia Alexeeva
Affiliations:
Federal Medical Research Center,St. Petersburg,Russian Federation
,
Simon Rule
Affiliations:
Department of Haematology,Derriford Hospital,Plymouth,United Kingdom
,
Tsvetan Biyukov
Affiliations:
Celgene International Sàrl,Boudry,Switzerland
,
Meera Patturajan
Affiliations:
Celgene Corporation,Summit,United States
,
Marie-Laure Casadebaig Bravo
Affiliations:
Celgene International Sàrl,Boudry,Switzerland
Luca Arcaini
Affiliations:
Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo & Department of Molecular Medicine,University of Pavia,Pavia,Italy
EHA Learning Center. Trneny M. Jun 12, 2015; 103096
Disclosure(s): Charles University Hospital
Prof. Dr. Marek Trneny
Prof. Dr. Marek Trneny

Access to EHA Members only content is an EHA membership benefit. Click here to join EHA or renew your membership here.


Abstract
Discussion Forum (0)
Rate & Comment (0)
Abstract: S107

Type: Oral Presentation

Presentation during EHA20: From 12.06.2015 11:45 to 12.06.2015 12:00

Location: Room A7

Background
Clinically meaningful and statistically significant improved activity was shown for lenalidomide, an immunomodulator with antineoplastic and antiproliferative effects, over single-agent investigator choice (IC) treatment in the MCL-002 (SPRINT) study of relapsed/refractory (R/R) patients with mantle cell lymphoma (MCL).

Aims
Evaluate the potential impact of prior therapy on progression-free survival (PFS) in R/R MCL patients randomized to lenalidomide vs IC.

Methods
Patients were randomized to lenalidomide (25 mg/day PO on days 1-21/28 days) or single-agent IC (rituximab, gemcitabine, fludarabine, chlorambucil, or cytarabine). The primary endpoint of this phase II study was PFS; prespecified exploratory analyses of PFS by subgroups were conducted.

Results
Following a median of 2 prior therapies, 254 R/R MCL patients were randomized 2:1 to lenalidomide (n=170) or IC (n=84). The preferred single-agent IC therapy was selected for each patient prior to randomization. Overall, the median PFS was significantly improved for lenalidomide vs IC (8.7 vs 5.2 months; HR=0.61, P=0.004). Exploratory analysis of PFS by central review based on selected IC treatment showed that lenalidomide provided a reduction in the risk of progression or death vs each IC treatment. Compared with lenalidomide and taking into account small patient numbers per IC group, the risk reduction in PFS was 22% vs rituximab (n=27), 56% vs gemcitabine (n=20), 42% vs fludarabine (n=18), 43% vs chlorambucil (n=11), and 8% vs cytarabine (n=8).

 

Subgroup analysis of PFS by central review based on prior treatment-related subgroups favored the use of lenalidomide overall. Several subgroups showed statistically improved PFS for lenalidomide over IC, including patients with ≥2 prior systemic antilymphoma therapies, >1 prior relapse, refractory to last prior treatment, prior rituximab exposure, no prior hyperCVAD±rituximab or stem cell transplantation, ≥6 months time from last therapy (≥230 days from last prior rituximab), and <3 years from diagnosis to study treatment. The only category without risk reduction (but statistically insignificant) was ≥4 prior systemic antilymphoma therapies, partly explained by low patient numbers in each arm.

 

Treatment group was the main effect associated with significantly better PFS by univariate Cox regression analysis (HR=0.619; P=0.004), and was highly significant in the multivariate analysis (HR=0.384). Other factors associated with significantly better PFS by both univariate and multivariate analysis were <3 prior systemic antilymphoma therapies, and ≥230 days from last prior rituximab.



Summary
Subgroup and regression analyses of the primary study endpoint PFS showed superiority for lenalidomide over IC therapy in providing consistent clinical benefit in patients with R/R MCL irrespective of prior treatment history.

Keyword(s): Imids, Mantle cell lymphoma

Session topic: Treatment and outcome in non-Hodgkin lymphomas
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings